Chemistry
Recent developments in nanoscience have opened up a number of possibilities in the world of drug delivery. One particular group of nanocarriers called cyclodextrins has been extensively studied in a recent project, CYCLON, and a new four-year ITN network, CycloN Hit has now been confirmed to continue this work
New nanotechnology solutions for drug delivery
The worldwide spread of antibiotic- resistant microorganisms can be viewed as
an ecological consequence of the
systematic use of antimicrobial agents. Resistant bacteria prevail in healthcare environments where antibiotic selective pressure is intensive. Novel therapeutic approaches
are therefore urgently
required to deliver the well-documented existing
and reduce drugs to protect them from
degradation, increase their bioavailability, reduce toxic side effects, increase patient compliance
treatment
duration and related costs. = In this
of main interest for sense, nanocarriers based on
cyclodextrins are particularly appealing for the delivery of antibiotics. This approach is
AT A GLANCE MAIN CONTACT tuberculosis, infections related to Salmonella
Typhimurium, Staphyloccocus aureus and for species most frequently implicated in hospital
negative rods. The CYCLON project (which finished
September 2013) aimed, through the training of young researchers within a highly competent and multidisciplinary network, to develop a new generation of multifunctional drug nanocarriers based on this
family of water The soluble and
biocompatible oligosaccharides, the cyclodextrins. thoroughly
nanocarriers were
delivery vehicles of especially
developments photoactive
studied and evaluated as anticancer drugs, ones. Extensive
in nanoscience provided
great opportunities to develop the next generation of pharmaceutical nanocarriers,
i.e. and drug aiming at delivery
nanosystems, combining a variety of properties
combating
cancer and other serious diseases such as viral infections. Following on from this, the CycloN Hit
Konstantina Yannakopoulou molecular structure-properties relations, host/guest interactions, synthetic modifications of cyclodextrins and their bio- and nano-applications.
Contact: Tel: +(30)-210-6503796 Email:
dyanna@chem.demokritos.gr Web:
http://itn-cyclon.eu/
66
ITN network will design and characterise the cyclodextrin-based nanocarriers, test their ability to encapsulate drugs and study their efficacy in vitro on bacteria and infected cells. The best
formulation
will be tested in vivo and scaled up. The overall objectives of the project are to take full advantage of nanotechnology and of the high level interdisciplinary expertise of
the partners involved to efficiently
encapsulate and protect antibiotics in nanocarriers to combat resistant bacteria, and study the mechanisms in biological systems using state-of-the art techniques. Using the most recent advances in the
nanomedicine field, the final goal of the CycloN Hit project will be to bring to the preclinical studies an antibiotic formulation for the treatment of tuberculosis and more tailored alternative therapeutic approaches for other resistant microorganisms.
Insight Publishers | Projects infections such as enteric gram- AT A GLANCE Project Information
Project Title: CYCLON: Novel multifunctional cyclodextrin-based nanocarriers for drug encapsulation and delivery as a strategy to overcome current therapeutic drawbacks
Project Objective: The objectives of the CYCLON project have been to provide top quality training to young researchers via top quality research in nanomedicine within a highly competent and multidisciplinary scientific network. The research succeeded in developing a collection of new, water soluble, biocompatible and multifunctional drug nanocarriers based on cyclodextrins, to be used as delivery vehicles of anticancer drugs, especially photoactive ones.
Project Duration and Timing: 4 years, Oct 2009 to Sept 2013
Project Funding: 2.4 M€ (FP7-PEOPLE ITN 2008 – Multipartner Network)
Project Partners: of Environmental Sciences, Prof.
Thorsteinn Loftsson
Salvatore Sortino
for Organic Synthesis and
Ericson
Fenyvesi
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68